OUTLOOK THERAPEUTICS, INC. Current Portion of Long-Term Debt
OUTLOOK THERAPEUTICS, INC. (OTLK) had Current Portion of Long-Term Debt of $422.13 million as of 2020-06-30, per its 10-Q filed 2020-08-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt, Current Maturities
us-gaap:LongTermDebtCurrent · last filed 2020-08-14
- 2020-06-30: Long-term Debt, Current Maturities $422.13M.
- 2019-09-30: Long-term Debt, Current Maturities $1.03B; Long-term Debt, Current Maturities as first filed $1.03M.
- 2019-06-30: Long-term Debt, Current Maturities $1.05M.
- 2019-03-31: Long-term Debt, Current Maturities $1.05M.
| Period end | Long-term Debt, Current Maturities | Long-term Debt, Current Maturities as first filed |
|---|---|---|
| 2020-06-30 | $422.13M 10-Q · filed 2020-08-14 | |
| 2019-09-30 | $1.03B 10-Q · filed 2020-08-14 | $1.03M 10-K · filed 2019-12-19 |
| 2019-06-30 | $1.05M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $1.05M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $56.54K 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $66.48K 10-K · filed 2019-12-19 | |
| 2018-06-30 | $86.73K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $102.91K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $118.76K 10-Q · filed 2018-02-14 | |
| 2017-09-30 | $52.60K 10-K · filed 2018-12-18 | |
| 2016-09-30 | $586.45K 10-K · filed 2017-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |